Mutations and Drug Resistance: Topo I and Irinotecan
Low efficacy of a particular class of anti-cancer agents is discussed in this article. The authors hypothesize that Topoisomerase I mutations cause a resistance to Irinotecan, a commonly used drug for the treatment of colon cancer. Article Source: Molecular Cancer New Topoisomerase I mutations are associated with resistance to camptothecin Abstract Background: Topoisomerase I (TOP1) is a nuclear enzyme that catalyzes the relaxation of supercoiled DNA during DNA replication and transcription. TOP1 is the molecular target of camptothecin and related…